AbbVie (ABBV) Outperforms Broader Market: What You Need to Know

AbbVie (ABBV) closed at $187.12 in the latest trading session, marking a +1.23% move from the prior day. The stock's change was more than the S&P 500's daily gain of 0.06%. Elsewhere, the Dow gained 0.41%, while the tech-heavy Nasdaq lost 0.39%. Shares of the drugmaker witnessed a gain of 0.59% over the previous month, beating the performance of the Medical sector with its loss of 1.83%, and underperforming the S&P 500's gain of 5.88%.The upcoming earnings release of AbbVie will be of great interest to investors. The company's earnings report is expected on July 31, 2025. The company is expected to report EPS of $2.9, up 9.43% from the prior-year quarter. At the same time, our most recent consensus estimate is projecting a revenue of $15.04 billion, reflecting a 3.97% rise from the equivalent quarter last year. For the annual period, the Zacks Consensus Estimates anticipate earnings of $11.98 per share and a revenue of $60.12 billion, signifying shifts of +18.38% and +6.72%, respectively, from the last year. Investors might also notice recent changes to analyst estimates for AbbVie. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook. Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system. Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 2.45% downward. As of now, AbbVie holds a Zacks Rank of #3 (Hold). In terms of valuation, AbbVie is currently trading at a Forward P/E ratio of 15.43. Its industry sports an average Forward P/E of 14.1, so one might conclude that AbbVie is trading at a premium comparatively. Meanwhile, ABBV's PEG ratio is currently 1.22. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. As the market closed yesterday, the Large Cap Pharmaceuticals industry was having an average PEG ratio of 1.22. The Large Cap Pharmaceuticals industry is part of the Medical sector. With its current Zacks Industry Rank of 48, this industry ranks in the top 20% of all industries, numbering over 250. The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions. Zacks' Research Chief Names "Stock Most Likely to Double"Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks